Modeling the Effects of Stroma on Clear Cell Renal Cell Carcinoma
Abstract
Clear cell renal cell carcinoma (ccRCC) is the 10th most common cancer. Surgical removal of the tumor is the primary treatment for the majority of patients, and is curative in over 50% of cases. However, therapeutic options are limited for the large number of patients whose cancer recurs. Development of new testing platforms in which patient tumors are established in cell culture provide the possibility to identify new drug targets in a patient-specific manner. In this study we have developed a tumor modeling system with the high fidelity to patient tumors by recreating multiple parameters of the tumor-of-origin such as cellular composition and extracellular matrix (ECM) composition. In proof-of-principle experiments we have used these patient-derived tumor replicas to screen for drug targets that interfere with the transition in the final phase of the cell cycle. We demonstrate that inhibition of FOXM1, PME1 and TMEM167A slow tumor growth using the compounds FDI-6, AMZ-30 and the natural product silibinin.
Document Details
- Document Type
- Technical Report
- Publication Date
- Dec 01, 2022
- Accession Number
- AD1202967
Entities
People
- Leif Oxburgh
Organizations
- The Rogosin Institute